NCT06045793Phase 2Terminated

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

Study sponsor: Tonix Pharmaceuticals, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-21Actual

Enrollment · participants3Actual

Source updated2025-06-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Cocaine Use; Cocaine Intoxication; Cocaine Toxicity; Cocaine Abuse; Cocaine Adverse Reaction

Treatments or interventions studied

TNX-1300 (Injection)DrugAlso known as Cocaine esterase
Placebo (Injection)Drug

Primary outcomes · main study measures

measure: Change from Baseline in Systolic BP at 60 minutes after dosing, comparing TNX-1300 to placebo with UC; description: Patients will undergo a Systolic BP assessment at Baseline and at 60 minutes after dosing.; timeFrame: 60 minutes after IV administration

History coverage

Imported research includes version dates later than the current official API record (2025-06-24). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history